Half-year report · HY
3101.TEDINET S100X28K
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥204.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥422.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥209.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥11.8bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥6.9bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.1bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥7.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥114m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥609.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥617.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥603.2bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥374.8bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥385.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥234.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥232.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥228.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥28.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥25.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥27.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥30.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥17.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥17.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥46.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥24.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥13.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥64.98 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.73 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.29 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.6% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥9.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥3.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥264m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥12.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥12.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.5bn |
| Life Sciencereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥16.6bn |
| Life Sciencereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥16.5bn |
| Life Sciencereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥89m |
| Life Sciencereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥149m |
| Real Estatereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.8bn |
| Real Estatereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Real Estatereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥576m |
| Real Estatereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥979m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥206.4bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥200.4bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.0bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥216.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥204.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥13.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥10.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥272m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥12.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥12.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.6bn |
| Life Sciencereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥17.3bn |
| Life Sciencereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥17.2bn |
| Life Sciencereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥53m |
| Life Sciencereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥905m |
| Real Estatereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Real Estatereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| Real Estatereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥581m |
| Real Estatereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥889m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥211.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥205.3bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.7bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥221.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥209.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 514
| Item | Context | Value | Unit |
|---|---|---|---|
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Notes regarding income taxes for global minimum tax (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |